Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase EARLY_PHASE1 1Phase 2 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 17Colorectal Neoplasms 15Colonic Neoplasms 8Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Skin Neoplasms 4Rectal Neoplasms 4Neoplasms 4Lung Neoplasms 3Neoplasm Metastasis 2Gastrointestinal Neoplasms 2Digestive System Neoplasms 2Thyroid Neoplasms 1Solid Tumors 1Skin Diseases 1Rectal Diseases 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Lymphatic Metastasis 1Leukemia, Hairy Cell 1Intestinal Neoplasms 1Intestinal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Gastrointestinal Diseases 1Disease Progression 1Digestive System Diseases 1Colonic Diseases 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 16Nivolumab 15Ipilimumab 12cemiplimab 10aldesleukin 6Interleukin-2 6Cyclophosphamide 6fludarabine 5fludarabine phosphate 4encorafenib 4binimetinib 4Blood Specimen Collection 4avelumab 3Sirolimus 3trametinib 2spartalizumab 2lifileucel 2dabrafenib 2atezolizumab 2Vemurafenib 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Prednisone 2Niacinamide 2Exercise 2Everolimus 2Dermoscopy 2Biopsy 2urelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Skin Neoplasms × encorafenib × 1 year × Clear all
NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Pfizer

Phase 3 Active not recruiting
257 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT05926960 2026-03-09

PORTSIDE

Pfizer

Phase 2 Terminated
38 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT01909453 2026-02-27

COLUMBUS

Pfizer

Phase 3 Completed
921 enrolled 48 charts 1 FDA
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
14 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡